Thank you. That was a good read. Years ago I be
Post# of 72440
Years ago I believed that Brilacidin could make it to market through BARDA but I wasn’t aware of the hurdles with DRGs and price points.
I still believe Brilacidin will become a household name like aspirin. The potential is just too great for it to stay under the radar. The upcoming trial will bring new attention to it and there are other pathways outside the United States to reach a market and financial success. It’s coming and I don’t doubt it for a second.